English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew work from a team at Roswell Park Comprehensive Cancer Center will help guide the care of patients with neuroendocrine tumors, or NETs. In a poster presentation at the American Society of Clinical Oncology (ASCO) virtual Annual Meeting 2021, Abhay Singh, MD, MPH, and colleagues outline their discovery of a potential biomarker to predict which patients are likely to experience blood toxicity side effects from a new targeted radiation treatment, peptide receptor radionuclide therapy (PRRT).
Tag: neuroendocrine cancers
Phosphoprotein biomarkers to guide cancer therapy are identified
Post-translational modification analysis may broadly identify new biomarkers of cancer drivers for a much more precise prediction of patient responses to treatments. A recent study demonstrates this diagnostic alternative for neuroendocrine neoplasms driven by a protein kinase called Cdk5.
Roswell Park Studies Highlight Emerging Treatment Options for Neuroendocrine Tumors
Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, highlight possible new treatment options for patients with neuroendocrine tumors (NETs) — a rare and hard-to-treat cancer.